Table 1. Patients characteristics (n = 37).
| Patients characteristics | Number (%) | |
|---|---|---|
| Median age | years (range) | 57 (39–75) |
| Gender | Male | 17 (45.9%) |
| Female | 20 (54.1%) | |
| Pathology | Adenocarcinoma | 36 (97.3%) |
| Non-small cell carcinoma | 1 (2.7%) | |
| Epidermal growth factor receptor (EGFR) mutation | No mutation | 9 (24.3%) |
| Mutation | ||
| deletion 19 | 9 (24.3%) | |
| missense mutation 21 (L858R) | 10 (27.0%) | |
| other mutation | 3 (8.1%) | |
| Not assessed | 6 (16.2%) | |
| Tyrosine kinase inhibitor (TKI) use | Gefitinib | 19 (51.4%) |
| Erlotinib | 14 (37.8%) | |
| Afatinib | 1 (2.7%) | |
| No use | 3 (8.1%) | |
| TKI line (among 34 patients with TKI use) | 1st line | 6 (17.6%) |
| 2nd line | 19 (55.9%) | |
| 3rd line | 8 (23.5%) | |
| 4th line | 1 (2.9%) | |
| Best response to TKI (among 34 patients with TKI use) | PR | 17 (55.0%) |
| SD | 6 (17.6%) | |
| PD | 8 (23.5%) | |
| Not assessed | 3 (8.8%) | |
PR: partial response; SD: stable disease; PD: progressive disease;